Drug profile · INN
acetazolamide
DIAMOX
acetazolamide (DIAMOX) is a carbonic anhydrase xii inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — acetazolamide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 4
- Data quality
- 0.89
Quick answer
acetazolamide (DIAMOX) is a carbonic anhydrase xii inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbonic anhydrase XII inhibitor
Primary target: Carbonic anhydrase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12419888
Methods of treating elevated plasma cholesterol
granted -
US 11639490
Device and method for producing and purifying exosomes
granted -
US 10788490
Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits
granted -
US 9789134
Agent for the selective adjustment of blood lipids
granted
Frequently asked questions
What is acetazolamide?
acetazolamide (DIAMOX) is a carbonic anhydrase xii inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acetazolamide?
DIAMOX is a marketed brand name for acetazolamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acetazolamide?
acetazolamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.